We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead & Galapagos Announce Positive Data on Filgotinib
Read MoreHide Full Article
Gilead Sciences, Inc. (GILD - Free Report) and Galapagos NV (GLPG - Free Report) announced that the phase II study, EQUATOR, on pipeline candidate, filgotinib achieved its primary endpoint of improvement in the signs and symptoms of psoriatic arthritis at Week 16, as assessed by the American College of Rheumatology 20 percent improvement score (ACR20).
The EQUATOR trial, initiated by Galapagos in April 2017, is a multicenter randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of the selective JAK1 inhibitor filgotinib in adult patients with moderately to severely active psoriatic arthritis.
The data from the study depicted an ACR20 response of 80% for filgotinib versus 33% for placebo. Additionally, the ACR50 and ACR70 responses at Week 16 were also significantly higher for filgotinib than placebo. Filgotinib was generally well-tolerated in the trial and no new safety signals were observed. However, there was one serious infection in the filgotinib group where a patient who experienced pneumonia with a fatal outcome and one other patient receiving filgotinib developed herpes zoster.
Both the companies plan to report the detailed results from the EQUATOR trial at a future scientific conference.
Concurrently, Gilead and Galapagos also announced that an independent Data Monitoring Committee (DMC) conducted a planned interim futility analysis of the phase IIb/IIII study, SELECTION, on filgotinib for the treatment of ulcerative colitis. The analysis was conducted after 350 patients completed the induction period in the phase IIb portion of the study. The DMC recommended that the study should go on as planned into phase III at both the 100 mg and 200 mg once daily dose level in biologic-experienced and biologic-naïve patients. The multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of the selective JAK1 inhibitor filgotinib in adult patients, with moderately to severely active ulcerative colitis was initiated by Gilead in late 2016. Consequently, Gilead will pay $15 million to Galapagos for this progression from phase II to phase III in the SELECTION trial. The trial will enroll a total of 1,300 patients, targeted to be randomized to receive filgotinib 100 mg, 200 mg, or placebo once-daily administered for 58 weeks. The primary objective of SELECTION is to evaluate the efficacy of filgotinib as compared to placebo in establishing EBS (endoscopy, bleeding, stool) remission at Week 10.
Both Galapagos and Gilead entered into a global collaboration for the development and commercialization of filgotinib in inflammatory indications. The candidate is also being evaluated in the ongoing phase III program, FINCH in rheumatoid arthritis, the phase III trial, DIVERSITY for Crohn’s disease (also small bowel and fistulizing Crohn’s disease phase II studies) among others.
Given the persistent decline in HCV sales, Gilead is looking to newer avenues to help its top line. Gilead’s stock has lost 8.2% in the last six months as against the industry''s loss of 8.1%.
Gilead’s HCV franchise witnessed slowdown across key markets, including the United States and Europe, reflecting lower sales of Harvoni and Sovaldi as a result of competitive and pricing pressure. The franchise saw a significant plunge in sales due to new competition and fewer patient starts. Pricing has largely stabilized and market share will stabilize by mid-2018, while patient starts are expected to decline further. We note that Harvoni, Sovaldi and Epclusa face competition from AbbVie’s (ABBV - Free Report) Viekira Pak and Mayret, and Merck’s (MRK - Free Report) Zepatier among others.
Gilead is looking to solidify its presence in the gene therapy space. The initial uptake of Yescarta is also encouraging. Gilead is also intending to foray into the NASH market with pipeline candidates — selonsertib and filgotinib.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Gilead & Galapagos Announce Positive Data on Filgotinib
Gilead Sciences, Inc. (GILD - Free Report) and Galapagos NV (GLPG - Free Report) announced that the phase II study, EQUATOR, on pipeline candidate, filgotinib achieved its primary endpoint of improvement in the signs and symptoms of psoriatic arthritis at Week 16, as assessed by the American College of Rheumatology 20 percent improvement score (ACR20).
The EQUATOR trial, initiated by Galapagos in April 2017, is a multicenter randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of the selective JAK1 inhibitor filgotinib in adult patients with moderately to severely active psoriatic arthritis.
The data from the study depicted an ACR20 response of 80% for filgotinib versus 33% for placebo. Additionally, the ACR50 and ACR70 responses at Week 16 were also significantly higher for filgotinib than placebo. Filgotinib was generally well-tolerated in the trial and no new safety signals were observed. However, there was one serious infection in the filgotinib group where a patient who experienced pneumonia with a fatal outcome and one other patient receiving filgotinib developed herpes zoster.
Both the companies plan to report the detailed results from the EQUATOR trial at a future scientific conference.
Concurrently, Gilead and Galapagos also announced that an independent Data Monitoring Committee (DMC) conducted a planned interim futility analysis of the phase IIb/IIII study, SELECTION, on filgotinib for the treatment of ulcerative colitis. The analysis was conducted after 350 patients completed the induction period in the phase IIb portion of the study. The DMC recommended that the study should go on as planned into phase III at both the 100 mg and 200 mg once daily dose level in biologic-experienced and biologic-naïve patients. The multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of the selective JAK1 inhibitor filgotinib in adult patients, with moderately to severely active ulcerative colitis was initiated by Gilead in late 2016. Consequently, Gilead will pay $15 million to Galapagos for this progression from phase II to phase III in the SELECTION trial. The trial will enroll a total of 1,300 patients, targeted to be randomized to receive filgotinib 100 mg, 200 mg, or placebo once-daily administered for 58 weeks. The primary objective of SELECTION is to evaluate the efficacy of filgotinib as compared to placebo in establishing EBS (endoscopy, bleeding, stool) remission at Week 10.
Both Galapagos and Gilead entered into a global collaboration for the development and commercialization of filgotinib in inflammatory indications. The candidate is also being evaluated in the ongoing phase III program, FINCH in rheumatoid arthritis, the phase III trial, DIVERSITY for Crohn’s disease (also small bowel and fistulizing Crohn’s disease phase II studies) among others.
Given the persistent decline in HCV sales, Gilead is looking to newer avenues to help its top line. Gilead’s stock has lost 8.2% in the last six months as against the industry''s loss of 8.1%.
Gilead’s HCV franchise witnessed slowdown across key markets, including the United States and Europe, reflecting lower sales of Harvoni and Sovaldi as a result of competitive and pricing pressure. The franchise saw a significant plunge in sales due to new competition and fewer patient starts. Pricing has largely stabilized and market share will stabilize by mid-2018, while patient starts are expected to decline further. We note that Harvoni, Sovaldi and Epclusa face competition from AbbVie’s (ABBV - Free Report) Viekira Pak and Mayret, and Merck’s (MRK - Free Report) Zepatier among others.
Gilead is looking to solidify its presence in the gene therapy space. The initial uptake of Yescarta is also encouraging. Gilead is also intending to foray into the NASH market with pipeline candidates — selonsertib and filgotinib.
Zacks Rank
Gilead currently carries a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>